Literature DB >> 24611672

Mean remaining life span: a new clinically relevant parameter to assess the quality of transfused red blood cells.

Denison J Kuruvilla1, Demet Nalbant, John A Widness, Peter Veng-Pedersen.   

Abstract

BACKGROUND: The quality of transfused red blood cells (RBCs) to treat anemia depends on its potential for oxygen delivery, governed by two properties: 1) initial posttransfusion recovery and 2) life span of initially surviving RBCs. The latter property is poorly evaluated by the traditional mean potential life span (MPL) or mean cell age (MA), because these parameters do not evaluate how long transfused RBCs remain in circulation. Furthermore, evaluation of MPL is based on two problematic assumptions regarding transfused RBCs: 1) they were produced at a constant steady-state rate and 2) they have similar storage life spans. STUDY DESIGN AND METHODS: This work introduces a new parameter, the mean remaining life span (MRL) to quantify transfused RBC survival (TRCS) and presents a simple algorithm for its evaluation. The MRL was calculated for four adult subjects with sickle cell disease and four adult diabetic and nondiabetic subjects using RBC survival data sets with existing TRCS parameters.
RESULTS: The RBC survival curves in the sickle cell subjects were nonlinear with rapid decline in survival within the first 5 days. The MRL was approximately 4.6 days. Thus, the MRL was indicative of the survival of all transfused RBCs. For the diabetic and nondiabetic subjects, the RBC disappearance curves did not deviate substantially from a linear decline. Thus, the estimates for MRL ranging from 39 to 51 days are similar to the MA previously computed.
CONCLUSION: MRL overcomes limitations of previously proposed TRCS parameters, is simpler to calculate, and is physiologically and clinically more appropriate.
© 2014 AABB.

Entities:  

Mesh:

Year:  2014        PMID: 24611672      PMCID: PMC4404519          DOI: 10.1111/trf.12562

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  15 in total

1.  Red blood cell survival studies.

Authors:  G S EADIE; I W BROWN
Journal:  Blood       Date:  1953-12       Impact factor: 22.113

2.  Recovery and in vivo survival of human red cells; studies of red cells after storage up to six and one-fourth months at subzero temperatures.

Authors:  I W BROWN; H F HARDIN
Journal:  AMA Arch Surg       Date:  1953-03

Review 3.  Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part II).

Authors:  P Veng-Pedersen
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

Review 4.  Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part I).

Authors:  P Veng-Pedersen
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

Review 5.  Red blood cells intended for transfusion: quality criteria revisited.

Authors:  Claes F Högman; Harold T Meryman
Journal:  Transfusion       Date:  2006-01       Impact factor: 3.157

6.  Oxidative processes in red blood cells from normal and diabetic individuals.

Authors:  M Bryszewska; I B Zavodnik; A Niekurzak; K Szosland
Journal:  Biochem Mol Biol Int       Date:  1995-10

7.  Recommended method for radioisotope red-cell survival studies. International Committee for Standardization in Haematology.

Authors: 
Journal:  Br J Haematol       Date:  1980-08       Impact factor: 6.998

Review 8.  Oxidant stress and haemolysis of the human erythrocyte.

Authors:  Marco L A Sivilotti
Journal:  Toxicol Rev       Date:  2004

9.  Effect of prophylactic transfusion of stored RBCs on oxygen reserve in response to acute isovolemic hemorrhage in a rodent model.

Authors:  M S d'Almeida; D Gray; C Martin; C G Ellis; I H Chin-Yee
Journal:  Transfusion       Date:  2001-07       Impact factor: 3.157

10.  Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c.

Authors:  Robert M Cohen; Robert S Franco; Paramjit K Khera; Eric P Smith; Christopher J Lindsell; Peter J Ciraolo; Mary B Palascak; Clinton H Joiner
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

View more
  4 in total

Review 1.  Development, validation, and potential applications of biotinylated red blood cells for posttransfusion kinetics and other physiological studies: evidenced-based analysis and recommendations.

Authors:  Donald M Mock; Demet Nalbant; Svetlana V Kyosseva; Robert L Schmidt; Guohua An; Nell I Matthews; Alexander P J Vlaar; Robin van Bruggen; Dirk de Korte; Ronald G Strauss; José A Cancelas; Robert S Franco; Peter Veng-Pedersen; John A Widness
Journal:  Transfusion       Date:  2018-05-16       Impact factor: 3.157

2.  A Method to Evaluate Fetal Erythropoiesis from Postnatal Survival of Fetal RBCs.

Authors:  Denison J Kuruvilla; John A Widness; Demet Nalbant; Robert L Schmidt; Donald M Mock; Peter Veng-Pedersen
Journal:  AAPS J       Date:  2015-05-28       Impact factor: 4.009

Review 3.  Measurement of posttransfusion red cell survival with the biotin label.

Authors:  Donald M Mock; John A Widness; Peter Veng-Pedersen; Ronald G Strauss; Jose A Cancelas; Robert M Cohen; Christopher J Lindsell; Robert S Franco
Journal:  Transfus Med Rev       Date:  2014-04-05

4.  Models for the red blood cell lifespan.

Authors:  Rajiv P Shrestha; Joseph Horowitz; Christopher V Hollot; Michael J Germain; John A Widness; Donald M Mock; Peter Veng-Pedersen; Yossi Chait
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-04-02       Impact factor: 2.745

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.